Restrictive fluid management strategies and outcomes in liver transplantation: a systematic review.
François Martin Carrier, Michaël Chassé, Han Ting Wang...
https://pubmed.ncbi.nlm.nih.gov/31556006/Actively Recruiting
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2026-07-10
866
Participants Needed
4
Research Sites
52 weeks
Total Duration
This research aims to compare two fluid management strategies during liver transplantation for adults with end-stage liver disease ESLD. It evaluates whether a low splanchnic blood volume restrictive fluid management approach, combined with phlebotomy and use of blood pressure medications during surgery, improves patient recovery and reduces severe postoperative complications compared to a more liberal fluid administration strategy. The study includes patients undergoing liver transplantation and follows them for up to 12 months after surgery. Participants are randomly assigned to one of two groups the restrictive group receives phlebotomy at the start of surgery with limited fluids and medications to maintain blood pressure, while the liberal group follows a goal-directed therapy that administers fluids to optimize heart output. Blood collected during phlebotomy is transfused back during reperfusion in the restrictive group. Both groups receive fluids to replace blood loss or treat severe instability. The study includes an initial pilot phase and then a larger phase to assess these approaches. During the study, participants are monitored from surgery through their hospital stay and up to one year post-transplant. Researchers will assess severe complications within 30 days after surgery, blood transfusions, blood loss, quality of recovery at 7 days, kidney function, graft health, infection, ICU stays, hospital length, readmissions, survival, quality of life, and costs. Follow-up includes clinical evaluations and quality of life measures to understand the impact of the fluid management strategy on recovery and long-term outcomes.
CONDITIONS
Restrictive Fluid Management In Liver Transplantation (REFIL)
M
Manuela Mbacfou, MSc
F
François Martin Carrier, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are evaluated to determine if they meet the eligibility criteria to join the trial.
1 visit (in-person)
Duration - Duration of surgery and hospital stay up to 30 days
Participants undergo liver transplantation surgery and receive one of the two fluid management strategies during the procedure.
Hospital monitoring through surgery and up to 30 days post-operation
Duration - 12 months
Participants are followed for 12 months after surgery to assess recovery, quality of life, complications, and survival.
Regular follow-up visits during the year after surgery
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
François Martin Carrier, Michaël Chassé, Han Ting Wang...
https://pubmed.ncbi.nlm.nih.gov/31556006/Anup Parikh, Kenneth W Washburn, Lea Matsuoka...
https://pubmed.ncbi.nlm.nih.gov/25991395/Christina H Shin, Dustin R Long, Duncan McLean...
https://pubmed.ncbi.nlm.nih.gov/28288059/Julie K M Thacker, William K Mountford, Frank R Ernst...
https://pubmed.ncbi.nlm.nih.gov/26565138/Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor